Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 2215 publications.

Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.

Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States. Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.

Lin SH, Ahn M, Nagar S, Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI, Davis K, Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study. Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.

Rothwell B, Sheikh K, Knight C, Kamgar F, Jain R, Mamtani R, Kurt M, Poretta T, Broughton E, Teitsson S. Cost-utility of Nivolumab versus observation for the adjuvant treatment of Urothelial Carcinoma (UC) for patients who are at high-risk of recurrence: a United States (US) payer perspective. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun;.

Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F. Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Herring W, Mladsi DM, Ronquest NA. AD valorem: Alzheimer's disease, atopic dermatitis, and challenges for value assessment in chronic conditions. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Ciepielewska M, Hagan M, Houghton K, Hitchens A, Ansquer V, Silver SM. Real-world treatment patterns and healthcare resource utilization among patients diagnosed with erythropoietic protoporphyria and x-linked protoporphyria: results from a US electronic medical records study. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Saidha S, Bell J, Harold SE, Marcano Belisario JS, Hawe E, Shao Q, Wyse K, Maiese EM. A systematic literature review of immunoglobulin levels among B-cell–depleting therapies and risk of infections in relapsing multiple sclerosis. Poster presented at the 2022 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting; June 1, 2022. National Harbor, MD.

Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H. Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Poster presented at the ISPOR 2022 Conference; May 18, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun.

Hartley L, Harold S, Hawe E. A systematic review of the efficacy, safety and immunogenicity of plague vaccines. Poster presented at the ISPOR 2022 Conference; May 16, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022 Jun;40(6):601-32116. doi: 10.1007/s40273-021-01112-8

Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P. The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Harrison JE, Paulsen R, Acaster S, Herring W. Are we patient and care-partner centric enough in early Alzheimer's disease clinical trials? The potential limitations of using legacy clinical outcome assessments (COA) in the new era of Alzheimer's disease drug development. Presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC.

Davis AE, Earnshaw SR, Mullins CD. Budget impact analysis 1: a 6-step approach. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. Previously presented at the ISPOR 18th Annual European Congress.

Ronquest N, Paret K, Lucas A, Ciepielewska M, Hagan M. A review of analyses evaluating the economic impact of oral versus intravenous formulations. Poster presented at the ISPOR 2022 Conference; May 14, 2022. Washington, DC.

Anderson-Smits C, Mitchell S, Hawe E, Hartley L. Use of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy: a systematic literature review. Poster presented at the 2022 Peripheral Nerve Society (PNS) Annual Meeting; May 14, 2022. Miami, FL.

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 May 9;e0042522. doi: 10.1128/spectrum.00425-22

Sundaram V, Wasserman M, Palmborg A, McDade C, Dorange AC, Wilson M, Perdrizet J. Comparing the public health impact of the pediatric 15- and 20-valent pneumococcal conjugate vaccine in Sweden. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.

Sundaram V, Perdrizet J, Wasserman M, Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A. Comparing the public health impact of switching to pediatric 13-valent pneumococcal conjugate vaccine in the near-term and higher-valent pneumococcal conjugate vaccines in the long-term in the Netherlands. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.

Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 40th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 9, 2022. Athens, Greece.

DePree B, Houghton K, Shiozawa A, Esterberg E, Kim J, Mancuso S. Real-world treatment for menopausal symptoms in the US by practitioner type. Poster presented at the American College of Obstetricians and Gynecologists (ACOG) 2022 Annual Meeting; May 6, 2022. San Diego, CA.

Ardeshirrouhanifard S, An H, Goyal RK, Raji MA, Segal JB, Alexander GC, Mehta HB. Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016. Pharmacotherapy. 2022 May;42(5):375-86. doi: 10.1002/phar.2679

Perugini M, Johnson TJ, Beume TM, Dong OM, Guerino J, Hu H, Kerr K, Kindilien S, Nuijten M, Ofili TU, Taylor M, Wong A, Freijer K. Are we ready for a new approach to comparing coverage and reimbursement policies for medical nutrition in key markets: an ISPOR special interest group report. Value Health. 2022 May;25(5):677-84. doi: 10.1016/j.jval.2022.01.011

Barnett CL, Denton BT. Optimization of biomarker-based prostate cancer screening policies. In: Sze-chuan Suen, David Scheinker, Eva Enns, editors. Artificial intelligence for healthcare: interdisciplinary partnerships for analytics-driven improvements in a post-COVID world. Cambridge: United Kingdom. Cambridge University Press; 2022. p.141-58.

Perdizet J, da Silva Maia AS, Teixeira R, Sundaram V, Wasserman M, McDade C, Wilson M. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine paediatric national immunisation programme in Portugal. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.

Mikudina B, Vyse AJ, Czudek C, Ellsbury GF, Perdrizet J, Wasserman M, McDade C, Wilson M. Infant pneumococcal conjugate vaccine programs result in substantial cost-savings and cases averted in the United Kingdom. Poster presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 23, 2022. Lisbon, Portugal.

Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885

Dong OM, Poonnen PJ, Winski D, Reed S, Vashistha V, Bates J, Kelley MJ, Voora D. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022 Apr;25(4):582-94. doi: 10.1016/j.jval.2021.09.017

Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Apr 1;1-11. doi: 10.1080/21645515.2022.2040328

Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265

Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39.

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y

Flem E, Graham J, Yi Z, Wisloff T, Johnson KD. Cost and health impact analysis of herpes zoster vaccination in Norway. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-26. doi: 10.1080/14737167.2021.1973893

Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy. 2022 Mar;20(2):213-21. doi: 10.1007/s40258-021-00704-x

Ainsworth C, Higuchi K, Simou E, Guyot P, Greene N. Relative differences in brain volume loss with teriflunomide versus other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the ACTRIMS Forum 2022; February 24, 2022. West Palm Beach, FL.

Guynn I, Simon J, Anderson S, Klaman SL, Mullenix A, Cilenti D, Hassmiller Lich K. Tools for supporting the MCH Workforce in addressing complex challenges: a scoping review of system dynamics modeling in maternal and child health. Matern Child Health J. 2022 Feb 21. doi: 10.1007/s10995-022-03376-8

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Manag Care Spec Pharm. 2022 Feb;28(2):146-55. doi: 10.18553/jmcp.2022.cheers

Husereau D, Drummond M, Augustovski F, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, de Bekker-Grob E, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG. 2022 Feb;129(3):336-44. doi: 10.1111/1471-0528.17012

Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022 Jan 12;20(1):23. doi: 10.1186/s12916-021-02204-0

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswel C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu R-F, Staniszewska S, the CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022 Jan 11;376:e067975. doi: 10.1136/bmj-2021-067975

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy Pract. 2022 Jan 11;7(1). doi: 10.1177/23814683211061097

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022 Jan 11;38(1):e13. doi: 10.1017/S0266462321001732